HOME > November 11, 2019
Daily News
November 11, 2019
- Chuikyo Positive about Changing Rules to Set Sales Thresholds after Market Expansion Re-Pricing Applied
November 11, 2019
- Japan to Use September 2019 Market Price Data for 2020 Revisions, April 2018 NHI Prices as Baseline
November 11, 2019
- Satralizumab Submitted in Japan for NMOSD
November 11, 2019
- LDP Lawmakers to Launch Group to Reinstate HPV Vaccine Recommendation
November 11, 2019
- Esaxerenone Hits Primary Goal in Japan PIII Study for Diabetic Nephropathy: Daiichi Sankyo
November 11, 2019
- Ninlaro Meets Primary Endpoint as 1st-Line Maintenance Therapy for Multiple Myeloma: Takeda
November 11, 2019
- Nippon Kayaku Forecasts 4.3 Billion Yen Full-Year Sales for Biosimilars
November 11, 2019
- BI Japan and Nippon BI to Merge in January Next Year to Increase Management Efficiency
November 11, 2019
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
